Mark J. Ratain to Biomarkers, Tumor
This is a "connection" page, showing publications Mark J. Ratain has written about Biomarkers, Tumor.
Connection Strength
1.829
-
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity? Clin Cancer Res. 2012 Aug 15; 18(16):4219-21.
Score: 0.244
-
Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther. 2009 Feb; 85(2):134-5.
Score: 0.191
-
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6545-8.
Score: 0.176
-
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
Score: 0.153
-
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.
Score: 0.115
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.104
-
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2019 09 10; 37(26):2368-2377.
Score: 0.099
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.091
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.090
-
Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3.
Score: 0.079
-
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74.
Score: 0.077
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.075
-
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
Score: 0.072
-
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
Score: 0.070
-
Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol. 2014 Aug; 12(8):525-8.
Score: 0.070
-
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
Score: 0.052
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
Score: 0.025
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.023
-
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
Score: 0.013
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.012